[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Pages 10680-10681]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-4200]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(1), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2)(b) authorizing the importation of 
such substances, provide manufacturers holding registrations for the 
bulk manufacture of the substances an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on December 9, 2004, Lipomed Inc., One Broadway, Cambridge, 
Massachusetts 02142, made application by renewal to the Drug 
Enforcement Administration (DEA) for registration as an importer of the 
basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methaqualone (2565)........................  I
Gamma-Hydroxybutyric Acid (2010)...........  I
Lysergic acid diethylamide (7315)..........  I
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
3,4,5-Trimethoxyamphetamine (7390).........  I
4-Bromo-2-5-dimethoxyamphetamine (7391)....  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
2,5-Dimethoxy-4-ethylamphetamine (7399)....  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphet- amine (7405).  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
Acetyldihydrocodeine (9051)................  I
Dihydromorphine (9145).....................  I
Heroin (9200)..............................  I
Tilidine (9750)............................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Amobarbital (2125).........................  II
Secobarbital (2315)........................  II
Phencyclidine (7471).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Hydrocodone (9193).........................  II
Levorphanol (9220).........................  II
Methadone (9250)...........................  II
Dextropropoxphene (9273)...................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to import small reference standard quantities of 
finished commercial product from its sister company in Switzerland for 
distribution to its customers for drug testing and pharmaceutical 
research and development.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic classes of controlled substances may 
file written comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than April 4, 2005.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-43746), all applicants for 
registration to import basic class of any controlled substance in 
Schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration that the requirements for such registration 
pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), 
(c), (d), (e), and (f) are satisfied.


[[Page 10681]]


    Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-4200 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P